Comparable stake leader
Armen Shanafelt
SEC ownership of Surface Oncology, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001718108.
Disclosed value leader
Liisa I. Nogelo
Comparable rows
0/9
Latest evidence
28 Jun 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Armen Shanafelt
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
28 Jun 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001718108
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Surface Oncology, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Armen Shanafelt
Disclosed value leader
Liisa I. Nogelo
Comparable rows
0/9
Latest evidence
28 Jun 2022
3/4/5
Highest disclosed value: $50,455
9 rows are not safely comparable across share classes.
Showing 1-8 of 9 holder rows.
Quick read
Liisa I. Nogelo has the largest disclosed position value at $50.5K.
0 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Liisa I. Nogelo's linked filing trail.
Disclosed position value
Top 1
Liisa I. Nogelo
$50.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Armen Shanafelt |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
—
24,000 shares
|
— | 08 Jun 2022 |
| Liisa I. Nogelo |
3/4/5
Chief Legal Officer
|
—
class O/S missing
|
$50,455
53,675 shares
|
— | 21 Jul 2021 |
| Theresa Boni |
3/4/5
General Counsel & Secretary
|
—
class O/S missing
|
—
120,000 shares
|
— | 01 Apr 2022 |
| Carsten Brunn |
3/4/5
Director
|
—
class O/S missing
|
—
48,000 shares
|
— | 28 Jun 2022 |
| Benjamin Hickey |
3/4/5
Director
|
—
class O/S missing
|
—
24,000 shares
|
— | 08 Jun 2022 |
| Denice Torres |
3/4/5
Director
|
—
class O/S missing
|
—
24,000 shares
|
— | 08 Jun 2022 |
| Laurie Stelzer |
3/4/5
Director
|
—
class O/S missing
|
—
24,000 shares
|
— | 08 Jun 2022 |
| Ramy Ibrahim |
3/4/5
Director
|
—
class O/S missing
|
—
24,000 shares
|
— | 08 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 23 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Surface Oncology, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Liisa I. Nogelo
Net 12M change
$0
Latest report
08 Sep 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Liisa I. Nogelo | Chief Legal Officer | $50,455 | Mixed | 21 Jul 2021 | ||
| Laurie Stelzer | Director | Mixed | 08 Jun 2022 | |||
| Charles Elliott Sigal | Director | Mixed | 08 Sep 2023 | |||
| Denice Torres | Director | Mixed | 08 Jun 2022 | |||
| Jeff Goater | Director | Mixed | 08 Sep 2023 | |||
| Alison Oneill | Chief Medical Officer | Mixed | 08 Sep 2023 | |||
| Carsten Brunn | Director | Mixed | 28 Jun 2022 | |||
| Vito J. Palombella | Chief Scientific Officer | Mixed | 08 Sep 2023 | |||
| Benjamin Hickey | Director | Mixed | 08 Jun 2022 | |||
| Armen Shanafelt | Director, 10%+ Owner | Mixed | 08 Jun 2022 | |||
| David S. Grayzel | Director | Mixed | 08 Sep 2023 | |||
| Geoff Mcdonough | Director | Mixed | 08 Jun 2021 | |||
| Robert W. Ross | Chief Executive Officer, Director | Mixed | 08 Sep 2023 | |||
| Jessica Fees | Chief Financial Officer | Mixed | 08 Sep 2023 | |||
| Henry C. Rath | Chief Business Officer | Mixed | 08 Sep 2023 | |||
| Theresa Boni | General Counsel & Secretary | Mixed | 01 Apr 2022 | |||
| Chandra Adams | Deputy GC | Mixed | 08 Sep 2023 | |||
| Ramy Ibrahim | Director | Mixed | 08 Jun 2022 |
Recent insider transactions for Surface Oncology, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.